CompletedPhase 3

An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)

1,873 participantsStarted 2001-01

Plain-language summary

The purpose of this study is to evaluate whether treatment with an investigational drug as compared to placebo will reduce the risk of major cardiovascular events in patients with aortic stenosis.

Who can participate

Age range45 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 45 to 85 with mild abnormalities of the aortic valve as confirmed by an echocardiogram. Exclusion Criteria: * Patients previously in a trial using the study drug, or currently taking any medications that are not allowed in this study.

What they're measuring

Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events)

Timeframe: Entire follow-up (median = 4.35 years)

Trial details

NCT IDNCT00092677

SponsorOrganon and Co

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-04

Results submitted2009-03-31

View on ClinicalTrials.gov More Aortic Stenosis trials